Hiroshi Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroshi Kimura has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Koichi Asahi
Division of Advanced Community Based Care for Lifestyle Related Diseases, Fukushima Medical University, Fukushima, Japan
8 shared publicationsTsuyoshi Watanabe
Division of Advanced Community Based Care for Lifestyle Related Diseases, Fukushima Medical University, Fukushima, Japan
8 shared publicationsHirotaka Saito
Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima, Japan
7 shared publicationsJunichiro James Kazama
Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima, Japan
6 shared publicationsKenichi Tanaka
Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima City, Japan
6 shared publications- Kenichi Tanaka
Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima City, Japan
3 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (6) , e005581
High-density lipoprotein cholesterol and kidney disease progression in patients with type 2 diabetes mellitus: the Fukushima Cohort Study
Introduction: Dyslipidemia is a major risk factor for cardiovascular disease in type 2 diabetes mellitus (T2DM), but its association with kidney disease progression remains incompletely defined. Although low high-density lipoprotein cholesterol (HDL-C) has been linked to diabetic nephropathy, evidence regarding hard kidney outcomes is limited. We examined the associations between HDL-C and kidney events in patients with T2DM, in comparison with other lipid parameters. Research design and methods: A total of 1,033 patients with T2DM from the Fukushima Cohort Study were included. Participants were followed for kidney events, defined as a ≥50% decrease in estimated glomerular filtration rate (eGFR) or onset of kidney failure requiring kidney replacement therapy, and all-cause mortality over a median follow-up period of 5.3 years. Lipid parameters HDL-C, triglycerides (TG), low-density lipoprotein cholesterol, non-HDL-C, and TG/HDL-C ratio were categorized into quartiles and evaluated using Cox proportional hazards models, adjusted for age, sex, smoking history, history of cardiovascular disease, body mass index, systolic blood pressure, eGFR, hemoglobin A1c, and proteinuria. Results: The median patient age was 66 years, 56% were men, and the median eGFR was 68.6 mL/min/1.73 m 2 . After multivariable adjustment, patients in the lowest HDL-C quartile (<42 mg/dL) had significantly higher risks of kidney events (adjusted HR 2.61, 95% CI 1.32 to 5.14) and all-cause mortality (adjusted HR 2.27, 95% CI 1.16 to 4.42) than the reference group (HDL-C 49–58 mg/dL). A U-shaped association was observed between HDL-C and all-cause mortality. Subgroup and sensitivity analyses were consistent. No significant associations were observed for other lipid parameters with either kidney events or mortality. Conclusions: Low HDL-C levels were independently associated with kidney events and all-cause mortality in patients with T2DM. Future studies are warranted to clarify whether interventions targeting HDL-C can improve kidney disease progression in this high-risk population. Trial registration number: UMIN000040848.
- 1 November 2025
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 13 (6) , e005581
Open AccessHigh-density lipoprotein cholesterol and kidney disease progression in patients with type 2 diabetes mellitus: the Fukushima Cohort Study
Introduction: Dyslipidemia is a major risk factor for cardiovascular disease in type 2 diabetes mellitus (T2DM), but its association with kidney disease progression remains incompletely defined. Although low high-density lipoprotein cholesterol (HDL-C) has been linked to diabetic nephropathy, evidence regarding hard kidney outcomes is limited. We examined the associations between HDL-C and kidney events in patients with T2DM, in comparison with other lipid parameters. Research design and methods: A total of 1,033 patients with T2DM from the Fukushima Cohort Study were included. Participants were followed for kidney events, defined as a ≥50% decrease in estimated glomerular filtration rate (eGFR) or onset of kidney failure requiring kidney replacement therapy, and all-cause mortality over a median follow-up period of 5.3 years. Lipid parameters HDL-C, triglycerides (TG), low-density lipoprotein cholesterol, non-HDL-C, and TG/HDL-C ratio were categorized into quartiles and evaluated using Cox proportional hazards models, adjusted for age, sex, smoking history, history of cardiovascular disease, body mass index, systolic blood pressure, eGFR, hemoglobin A1c, and proteinuria. Results: The median patient age was 66 years, 56% were men, and the median eGFR was 68.6 mL/min/1.73 m 2 . After multivariable adjustment, patients in the lowest HDL-C quartile (<42 mg/dL) had significantly higher risks of kidney events (adjusted HR 2.61, 95% CI 1.32 to 5.14) and all-cause mortality (adjusted HR 2.27, 95% CI 1.16 to 4.42) than the reference group (HDL-C 49–58 mg/dL). A U-shaped association was observed between HDL-C and all-cause mortality. Subgroup and sensitivity analyses were consistent. No significant associations were observed for other lipid parameters with either kidney events or mortality. Conclusions: Low HDL-C levels were independently associated with kidney events and all-cause mortality in patients with T2DM. Future studies are warranted to clarify whether interventions targeting HDL-C can improve kidney disease progression in this high-risk population. Trial registration number: UMIN000040848.
- Open Access
- 8 July 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (10) , 1829-1835
Association of red blood cell distribution width/albumin ratio with renal prognosis among patients with type 2 diabetes mellitus: A retrospective cohort study
Introduction: The red blood cell distribution width/albumin ratio (RAR) has been reported to be a prognostic marker for adverse clinical outcomes. However, there is limited data on the relationship between RAR and renal function in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the effect of RAR on renal prognosis in patients with T2DM. Research Design and Methods: This retrospective cohort study included 907 patients with T2DM enrolled in the Fukushima Cohort Study, divided into two groups (high and low RAR) according to their baseline RAR. The association between RAR and renal events was assessed using Kaplan–Meier curves and multivariate Cox regression analyses. Receiver operating characteristic (ROC) curve analyses, as well as the net reclassification index (NRI) and integrated discrimination improvement (IDI), examined the differences between RAR and red blood cell distribution width (RDW) alone. Results: The high RAR group showed an increased risk of renal events in the Kaplan–Meier curve analysis. Compared with the low RAR group, the high RAR group showed an increased risk of renal events (adjusted hazard ratio [HR]: 3.40, 95% confidence interval: 1.76–6.57). RAR exhibited a significantly higher area under the curve (AUC), NRI, and IDI for renal events than RDW. Conclusion: We observed an association between high RAR and worse renal outcomes in patients with T2DM. RAR assessment may have potential utility as a predictive tool for renal prognosis.
- 8 July 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 16 (10) , 1829-1835
Open AccessAssociation of red blood cell distribution width/albumin ratio with renal prognosis among patients with type 2 diabetes mellitus: A retrospective cohort study
Introduction: The red blood cell distribution width/albumin ratio (RAR) has been reported to be a prognostic marker for adverse clinical outcomes. However, there is limited data on the relationship between RAR and renal function in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the effect of RAR on renal prognosis in patients with T2DM. Research Design and Methods: This retrospective cohort study included 907 patients with T2DM enrolled in the Fukushima Cohort Study, divided into two groups (high and low RAR) according to their baseline RAR. The association between RAR and renal events was assessed using Kaplan–Meier curves and multivariate Cox regression analyses. Receiver operating characteristic (ROC) curve analyses, as well as the net reclassification index (NRI) and integrated discrimination improvement (IDI), examined the differences between RAR and red blood cell distribution width (RDW) alone. Results: The high RAR group showed an increased risk of renal events in the Kaplan–Meier curve analysis. Compared with the low RAR group, the high RAR group showed an increased risk of renal events (adjusted hazard ratio [HR]: 3.40, 95% confidence interval: 1.76–6.57). RAR exhibited a significantly higher area under the curve (AUC), NRI, and IDI for renal events than RDW. Conclusion: We observed an association between high RAR and worse renal outcomes in patients with T2DM. RAR assessment may have potential utility as a predictive tool for renal prognosis.
- Open Access
- 14 March 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (5) , 676-696
Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis
Key Points: Sevelamer was associated with lower all-cause mortality compared with calcium-based agents. Sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality compared with other phosphate-lowering agents. Sucroferric oxyhydroxide and lanthanum were associated with slower progression of coronary artery calcium score compared with calcium-based agents. Background: It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients. Methods: From the CENTRAL, MEDLINE, Embase, and ClinicalTrial.gov databases, randomized controlled trials using oral phosphate-lowering agents on adult patients requiring maintenance dialysis were extracted. The treatment period was required for 8 or more weeks, and the risk of bias was assessed according to the Cochrane Collaboration method. The outcomes were all-cause mortality, cardiovascular mortality, gastrointestinal events, fracture, coronary artery calcium score (CACS), serum calcium, phosphate, intact parathyroid hormone, and bicarbonate levels. A network meta-analyses using multivariate random-effects models were performed for assessing the comparative effectiveness. The ranking of the phosphate-lowering agents was assessed using a surface under the cumulative ranking curve. Results: A total of 70 randomized controlled trials involving 15,551 participants were included. Eleven phosphate-lowering agents including calcium-based agents, sevelamer, bixalomer, lanthanum, sucroferric oxyhydroxide, ferric citrate, tenapanor, magnesium, nicotinamide, aluminum, and sucralfate were assessed. Sevelamer was significantly associated with lower all-cause mortality compared with calcium-based agents (risk ratio [95% confidence interval]: 0.59 [0.37 to 0.94]), and sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality on the basis of the surface under the cumulative ranking curve. The risk of gastrointestinal events was the highest with nicotinamide, followed by sucroferric oxyhydroxide. Compared with calcium-based agents, CACS was significantly lower among those on lanthanum and sucroferric oxyhydroxide (standardized mean difference [95% confidence interval]: −0.26 [−0.52 to −0.01] and −0.50 [−0.95 to−0.06], respectively). Serum calcium levels were higher, and serum intact parathyroid hormone levels were lower in patients treated with calcium-based agents. Except for sevelamer, serum bicarbonate levels for all other agents were higher compared with placebo. Conclusions: Compared with calcium-based agents, sevelamer was associated with lower all-cause mortality, and sucroferric oxyhydroxide and lanthanum were associated with slower progression of CACS. Potential benefits and harms should be considered when selecting phosphate-lowering agents (International prospective register of systematic reviews: CRD42022328388).
- 14 March 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (5) , 676-696
Open AccessEfficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis
Key Points: Sevelamer was associated with lower all-cause mortality compared with calcium-based agents. Sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality compared with other phosphate-lowering agents. Sucroferric oxyhydroxide and lanthanum were associated with slower progression of coronary artery calcium score compared with calcium-based agents. Background: It is necessary to update the evidence of each phosphate-lowering agent on dialysis patients. Methods: From the CENTRAL, MEDLINE, Embase, and ClinicalTrial.gov databases, randomized controlled trials using oral phosphate-lowering agents on adult patients requiring maintenance dialysis were extracted. The treatment period was required for 8 or more weeks, and the risk of bias was assessed according to the Cochrane Collaboration method. The outcomes were all-cause mortality, cardiovascular mortality, gastrointestinal events, fracture, coronary artery calcium score (CACS), serum calcium, phosphate, intact parathyroid hormone, and bicarbonate levels. A network meta-analyses using multivariate random-effects models were performed for assessing the comparative effectiveness. The ranking of the phosphate-lowering agents was assessed using a surface under the cumulative ranking curve. Results: A total of 70 randomized controlled trials involving 15,551 participants were included. Eleven phosphate-lowering agents including calcium-based agents, sevelamer, bixalomer, lanthanum, sucroferric oxyhydroxide, ferric citrate, tenapanor, magnesium, nicotinamide, aluminum, and sucralfate were assessed. Sevelamer was significantly associated with lower all-cause mortality compared with calcium-based agents (risk ratio [95% confidence interval]: 0.59 [0.37 to 0.94]), and sucroferric oxyhydroxide and tenapanor were estimated to rank high in lowering all-cause mortality on the basis of the surface under the cumulative ranking curve. The risk of gastrointestinal events was the highest with nicotinamide, followed by sucroferric oxyhydroxide. Compared with calcium-based agents, CACS was significantly lower among those on lanthanum and sucroferric oxyhydroxide (standardized mean difference [95% confidence interval]: −0.26 [−0.52 to −0.01] and −0.50 [−0.95 to−0.06], respectively). Serum calcium levels were higher, and serum intact parathyroid hormone levels were lower in patients treated with calcium-based agents. Except for sevelamer, serum bicarbonate levels for all other agents were higher compared with placebo. Conclusions: Compared with calcium-based agents, sevelamer was associated with lower all-cause mortality, and sucroferric oxyhydroxide and lanthanum were associated with slower progression of CACS. Potential benefits and harms should be considered when selecting phosphate-lowering agents (International prospective register of systematic reviews: CRD42022328388).
- 16 July 2024
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 29 (1) , 12-22
Post‐dialysis fatigue predicts all‐cause mortality in patients on chronic hemodialysis
Introduction: Fatigue is reportedly associated with a poor prognosis in dialysis patients. The aim of the present study was to investigate whether fatigue on dialysis days or non‐dialysis days is associated with mortality in patients on chronic hemodialysis.Methods: This was a prospective study of 134 hemodialysis patients. The level of fatigue was evaluated using a visual analog scale (VAS). The association between high fatigue evaluated by the highest quartile of the VAS value and all‐cause death was investigated.Results: The fatigue scale score was significantly higher on dialysis than on non‐dialysis days. During the follow‐up period (median 6.8 years), 42 patients died. Patients with high post‐dialysis fatigue in the higher quartiles died more frequently compared to those with in the lower quartiles (p = 0.012). Multivariate Cox regression analysis showed that high post‐dialysis fatigue was an independent predictor of all‐cause death (adjusted hazard ratio 2.12, 95% confidence interval 1.10–4.07).Conclusion: Higher post‐dialysis fatigue is related to increased mortality.
- 16 July 2024
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 29 (1) , 12-22
Post‐dialysis fatigue predicts all‐cause mortality in patients on chronic hemodialysis
Introduction: Fatigue is reportedly associated with a poor prognosis in dialysis patients. The aim of the present study was to investigate whether fatigue on dialysis days or non‐dialysis days is associated with mortality in patients on chronic hemodialysis.Methods: This was a prospective study of 134 hemodialysis patients. The level of fatigue was evaluated using a visual analog scale (VAS). The association between high fatigue evaluated by the highest quartile of the VAS value and all‐cause death was investigated.Results: The fatigue scale score was significantly higher on dialysis than on non‐dialysis days. During the follow‐up period (median 6.8 years), 42 patients died. Patients with high post‐dialysis fatigue in the higher quartiles died more frequently compared to those with in the lower quartiles (p = 0.012). Multivariate Cox regression analysis showed that high post‐dialysis fatigue was an independent predictor of all‐cause death (adjusted hazard ratio 2.12, 95% confidence interval 1.10–4.07).Conclusion: Higher post‐dialysis fatigue is related to increased mortality.
- Open Access
- 22 September 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-7
Impact of red blood cell distribution width–albumin ratio on prognosis of patients with CKD
The red blood cell distribution width–albumin ratio (RAR) is a prognostic factor for adverse outcomes in various populations. However, whether RAR is associated with renal outcomes remains unclear. Therefore, we aimed to investigate the impact of RAR on the prognosis in patients with chronic kidney disease (CKD). We conducted a retrospective cohort study using 997 CKD patients who were enrolled in the Fukushima Cohort Study. Patients were categorized into tertiles (T1-3) according to the baseline RAR. The associations of RAR with end-stage kidney disease (ESKD) were assessed using Kaplan–Meier curves and multivariable cox regression analyses. Receiver operating characteristic (ROC) curves were performed to test whether significant differences were present between red cell distribution width (RDW) and RAR. The median age was 66, 57% were men, the median eGFR was 47.8 ml/min/1.73 m2, and the median value of RAR was 3.5. The higher RAR group showed an increased risk for ESKD in the Kaplan–Meier curve analysis. Compared to the lowest RAR group, higher RAR groups had a higher risk of ESKD (hazard ratio [HR] 1.37, 95% CI 0.68–2.78 and 2.92, 95% CI 1.44–5.94) for T2 and T3 groups, respectively. ROC curve analysis proved that the discriminating ability of RAR for ESKD was superior to RDW. A higher RAR value was associated with worse renal outcomes in patients with CKD. RAR could be a convenient and useful prognostic marker for renal prognosis.
- 22 September 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-7
Open AccessImpact of red blood cell distribution width–albumin ratio on prognosis of patients with CKD
The red blood cell distribution width–albumin ratio (RAR) is a prognostic factor for adverse outcomes in various populations. However, whether RAR is associated with renal outcomes remains unclear. Therefore, we aimed to investigate the impact of RAR on the prognosis in patients with chronic kidney disease (CKD). We conducted a retrospective cohort study using 997 CKD patients who were enrolled in the Fukushima Cohort Study. Patients were categorized into tertiles (T1-3) according to the baseline RAR. The associations of RAR with end-stage kidney disease (ESKD) were assessed using Kaplan–Meier curves and multivariable cox regression analyses. Receiver operating characteristic (ROC) curves were performed to test whether significant differences were present between red cell distribution width (RDW) and RAR. The median age was 66, 57% were men, the median eGFR was 47.8 ml/min/1.73 m2, and the median value of RAR was 3.5. The higher RAR group showed an increased risk for ESKD in the Kaplan–Meier curve analysis. Compared to the lowest RAR group, higher RAR groups had a higher risk of ESKD (hazard ratio [HR] 1.37, 95% CI 0.68–2.78 and 2.92, 95% CI 1.44–5.94) for T2 and T3 groups, respectively. ROC curve analysis proved that the discriminating ability of RAR for ESKD was superior to RDW. A higher RAR value was associated with worse renal outcomes in patients with CKD. RAR could be a convenient and useful prognostic marker for renal prognosis.
- 27 December 2022
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (3) , 272-278
Association of polypharmacy with incidence of CKD: a retrospective cohort study
Background Polypharmacy is common in patients with chronic kidney disease (CKD) and is associated with a decline in kidney function. However, its impact on patients without CKD has not been adequately elucidated. Therefore, we aimed to investigate the association between polypharmacy and the incidence of CKD. Methods We conducted retrospective cohort study using 1221 participants who were enrolled in the Fukushima Cohort Study with one or more risk factors of CKD, an estimated glomerular filtration rate (eGFR) of ≥ 60 mL/min/1.73 m2, and without proteinuria. Participants were categorized into three groups based on the number of medications: non-polypharmacy, 0–4 medications; polypharmacy, 5–9 medications; and hyper-polypharmacy, ≥ 10 medications. Results The median age was 62 years, 49% were men, the median eGFR was 75.4 ml/min/1.73 m2, and the median number of medications was 5. Polypharmacy and hyper-polypharmacy were noted in 506 (41%) and 250 (20%) participants, respectively. During follow-up, 288 participants developed CKD and 67 cardiovascular events were observed. Compared to the non-polypharmacy group, the hyper-polypharmacy group had a higher risk of CKD and cardiovascular events. The adjusted hazard ratios were 1.41 (95% CI1.01–1.99) and 2.24 (95% CI1.05–4.78) for the incidence of CKD and cardiovascular events, respectively. Sensitivity analyses yielded similar findings for the restricted cubic spline function models. Conclusions Hyper-polypharmacy is associated with a higher risk of CKD and cardiovascular events.
- 27 December 2022
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 27 (3) , 272-278
Association of polypharmacy with incidence of CKD: a retrospective cohort study
Background Polypharmacy is common in patients with chronic kidney disease (CKD) and is associated with a decline in kidney function. However, its impact on patients without CKD has not been adequately elucidated. Therefore, we aimed to investigate the association between polypharmacy and the incidence of CKD. Methods We conducted retrospective cohort study using 1221 participants who were enrolled in the Fukushima Cohort Study with one or more risk factors of CKD, an estimated glomerular filtration rate (eGFR) of ≥ 60 mL/min/1.73 m2, and without proteinuria. Participants were categorized into three groups based on the number of medications: non-polypharmacy, 0–4 medications; polypharmacy, 5–9 medications; and hyper-polypharmacy, ≥ 10 medications. Results The median age was 62 years, 49% were men, the median eGFR was 75.4 ml/min/1.73 m2, and the median number of medications was 5. Polypharmacy and hyper-polypharmacy were noted in 506 (41%) and 250 (20%) participants, respectively. During follow-up, 288 participants developed CKD and 67 cardiovascular events were observed. Compared to the non-polypharmacy group, the hyper-polypharmacy group had a higher risk of CKD and cardiovascular events. The adjusted hazard ratios were 1.41 (95% CI1.01–1.99) and 2.24 (95% CI1.05–4.78) for the incidence of CKD and cardiovascular events, respectively. Sensitivity analyses yielded similar findings for the restricted cubic spline function models. Conclusions Hyper-polypharmacy is associated with a higher risk of CKD and cardiovascular events.
- Open Access
- 29 September 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Health-related behavioral changes and incidence of chronic kidney disease: The Japan Specific Health Checkups (J-SHC) Study
The transtheoretical model (TTM) is a commonly used model of health-related behavioral change. However, the practical effect of using this model for chronic kidney disease (CKD) self-management remains unclear. This study aimed to investigate the association between stages of change for lifestyle behavior and the incidence of CKD in the general Japanese population. A retrospective cohort study was conducted among 178,780 non-CKD participants aged 40–74 years who underwent annual health check-ups for two consecutive years between 2008 and 2009. Health behavior change was determined using questionnaires based on the TTM, which consists of five stages of change (precontemplation, contemplation, preparation, action, and maintenance). The exposure of interest was the change in stages between two years. Participants were categorized into 3 groups ‘improved’, ‘unchanged’, or ‘deteriorated’. The association between the change in stages and the incidence of CKD was examined using logistic regression analysis. After one year of follow-up, 20.0% of participants developed CKD. Participants in the deteriorated group showed a significantly higher risk of CKD incidence than in the improved group. Promoting the stage of change for healthy lifestyle behaviors evaluated by the TTM was associated with a risk reduction for the incidence of CKD.
- 29 September 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-8
Open AccessHealth-related behavioral changes and incidence of chronic kidney disease: The Japan Specific Health Checkups (J-SHC) Study
The transtheoretical model (TTM) is a commonly used model of health-related behavioral change. However, the practical effect of using this model for chronic kidney disease (CKD) self-management remains unclear. This study aimed to investigate the association between stages of change for lifestyle behavior and the incidence of CKD in the general Japanese population. A retrospective cohort study was conducted among 178,780 non-CKD participants aged 40–74 years who underwent annual health check-ups for two consecutive years between 2008 and 2009. Health behavior change was determined using questionnaires based on the TTM, which consists of five stages of change (precontemplation, contemplation, preparation, action, and maintenance). The exposure of interest was the change in stages between two years. Participants were categorized into 3 groups ‘improved’, ‘unchanged’, or ‘deteriorated’. The association between the change in stages and the incidence of CKD was examined using logistic regression analysis. After one year of follow-up, 20.0% of participants developed CKD. Participants in the deteriorated group showed a significantly higher risk of CKD incidence than in the improved group. Promoting the stage of change for healthy lifestyle behaviors evaluated by the TTM was associated with a risk reduction for the incidence of CKD.
- Open Access
- 16 September 2022
- Published by S. Karger AG in Nephron
- Vol. 147 (3-4) , 177-184
Impact of Potentially Inappropriate Medications on Kidney Function in Chronic Kidney Disease: Retrospective Cohort Study
Introduction: Chronic kidney disease (CKD) represents a major public health burden. Potential inappropriate medications (PIMs) are common in patients with CKD. However, its impact on kidney outcomes has not been adequately elucidated for middle-aged patients. This study aimed to clarify the prescription status of PIMs for middle-aged patients with CKD and its effect on kidney function decline. Methods: Using an administrative claims database in Japan, a retrospective cohort study was conducted among Japanese patients with CKD (aged 20–74) who underwent annual health check-ups at least three times between April 2008 and December 2020. PIM exposure was defined as medications to be avoided in older adults as defined by the 2019 American Geriatrics Society Beers Criteria. The association between the number of prescribed PIMs and the decline in estimated glomerular filtration rate (eGFR) was examined using logistic regression models adjusted for clinical characteristics and laboratory variables. Results: A total of 43,143 patients with CKD (mean age 57 years, median eGFR: 52 mL/min/1.73 m2) were analyzed, and approximately 40% of the patients were prescribed one or more PIMs. The most commonly prescribed PIMs were pain medications (18.5%), followed by gastrointestinal medications (9.8%), central nervous system medications (8.6%), and cardiovascular medications (8.6%). After adjustment, exposure to 2 or ≥3 PIMs was associated with an increased risk of 30% eGFR decline (adjusted odds ratio 1.71 [95% confidence interval, 1.24–2.37] and 1.65 [95% confidence interval, 1.08–2.52], respectively) as compared to the control group. Conclusion: This study showed that middle-aged patients with CKD who were prescribed ≥2 PIM had an increased risk of progression of CKD. Further studies are needed to analyze whether deprescribing steps contribute to reduce PIM prescriptions and prevent CKD progression.
- 16 September 2022
- Published by S. Karger AG in Nephron
- Vol. 147 (3-4) , 177-184
Open AccessImpact of Potentially Inappropriate Medications on Kidney Function in Chronic Kidney Disease: Retrospective Cohort Study
Introduction: Chronic kidney disease (CKD) represents a major public health burden. Potential inappropriate medications (PIMs) are common in patients with CKD. However, its impact on kidney outcomes has not been adequately elucidated for middle-aged patients. This study aimed to clarify the prescription status of PIMs for middle-aged patients with CKD and its effect on kidney function decline. Methods: Using an administrative claims database in Japan, a retrospective cohort study was conducted among Japanese patients with CKD (aged 20–74) who underwent annual health check-ups at least three times between April 2008 and December 2020. PIM exposure was defined as medications to be avoided in older adults as defined by the 2019 American Geriatrics Society Beers Criteria. The association between the number of prescribed PIMs and the decline in estimated glomerular filtration rate (eGFR) was examined using logistic regression models adjusted for clinical characteristics and laboratory variables. Results: A total of 43,143 patients with CKD (mean age 57 years, median eGFR: 52 mL/min/1.73 m2) were analyzed, and approximately 40% of the patients were prescribed one or more PIMs. The most commonly prescribed PIMs were pain medications (18.5%), followed by gastrointestinal medications (9.8%), central nervous system medications (8.6%), and cardiovascular medications (8.6%). After adjustment, exposure to 2 or ≥3 PIMs was associated with an increased risk of 30% eGFR decline (adjusted odds ratio 1.71 [95% confidence interval, 1.24–2.37] and 1.65 [95% confidence interval, 1.08–2.52], respectively) as compared to the control group. Conclusion: This study showed that middle-aged patients with CKD who were prescribed ≥2 PIM had an increased risk of progression of CKD. Further studies are needed to analyze whether deprescribing steps contribute to reduce PIM prescriptions and prevent CKD progression.
- Open Access
- 8 August 2022
- Published by Springer Nature in Research Square
Health-related behavioral changes and incidence of chronic kidney disease: The Japan Specific Health Checkups (J-SHC) Study
The transtheoretical model (TTM) is a commonly used model of health-related behavioral change. However, the practical effect of using this model for chronic kidney disease (CKD) self-management remains unclear. This study aimed to investigate the association between stages of change for lifestyle behavior and the incidence of CKD in the general Japanese population. A retrospective cohort study was conducted among 178,780 non-CKD participants aged 40–74 years who underwent annual health check-ups for two consecutive years between 2008 and 2009. Health behavior change was determined using questionnaires based on the TTM, which consists of five stages of change (precontemplation, contemplation, preparation, action, and maintenance). The exposure of interest was the change in stages between two years. Participants were categorized into 3 groups ‘improved’, ‘unchanged’, or ‘deteriorated’. The association between the change in stages and the incidence of CKD was examined using logistic regression analysis. After one year of follow-up, 20.0% of participants developed CKD. Participants in the deteriorated group showed a significantly higher risk of CKD incidence than in the improved group. Promoting the stage of change for healthy lifestyle behaviors evaluated by the TTM was associated with a risk reduction for the incidence of CKD.
- 8 August 2022
- Published by Springer Nature in Research Square
Open AccessHealth-related behavioral changes and incidence of chronic kidney disease: The Japan Specific Health Checkups (J-SHC) Study
The transtheoretical model (TTM) is a commonly used model of health-related behavioral change. However, the practical effect of using this model for chronic kidney disease (CKD) self-management remains unclear. This study aimed to investigate the association between stages of change for lifestyle behavior and the incidence of CKD in the general Japanese population. A retrospective cohort study was conducted among 178,780 non-CKD participants aged 40–74 years who underwent annual health check-ups for two consecutive years between 2008 and 2009. Health behavior change was determined using questionnaires based on the TTM, which consists of five stages of change (precontemplation, contemplation, preparation, action, and maintenance). The exposure of interest was the change in stages between two years. Participants were categorized into 3 groups ‘improved’, ‘unchanged’, or ‘deteriorated’. The association between the change in stages and the incidence of CKD was examined using logistic regression analysis. After one year of follow-up, 20.0% of participants developed CKD. Participants in the deteriorated group showed a significantly higher risk of CKD incidence than in the improved group. Promoting the stage of change for healthy lifestyle behaviors evaluated by the TTM was associated with a risk reduction for the incidence of CKD.
- 1 December 2021
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 16 (12) , 1797-1804
Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
Background and objective: Polypharmacy is common in patients with CKD and reportedly associated with adverse outcomes. However, its effect on kidney outcomes among patients with CKD has not been adequately elucidated. Hence, this investigation was aimed at exploring the association between polypharmacy and kidney failure requiring KRT. Design, setting, participants, and measurements: We retrospectively examined 1117 participants (median age, 66 years; 56% male; median eGFR, 48 ml/min per 1.73 m2) enrolled in the Fukushima CKD Cohort Study to investigate the association between the number of prescribed medications and adverse outcomes such as kidney failure, all-cause mortality, and cardiovascular events in Japanese patients with nondialysis-dependent CKD. Polypharmacy and hyperpolypharmacy were defined as the regular use of 5–9 and ≥10 medications per day, respectively. Results: The median number of medications was eight; the prevalence of polypharmacy and hyperpolypharmacy was each 38%. During the observation period (median, 4.8 years), 120 developed kidney failure, 153 developed cardiovascular events, and 109 died. Compared with the use of fewer than five medications, adjusted hazard ratios (95% confidence intervals) associated with polypharmacy and hyperpolypharmacy were 2.28 (1.00 to 5.21) and 2.83 (1.21 to 6.66) for kidney failure, 1.60 (0.85 to 3.04) and 3.02 (1.59 to 5.74) for cardiovascular events, and 1.25 (0.62 to 2.53) and 2.80 (1.41 to 5.54) for all-cause mortality. Conclusions: The use of a high number of medications was associated with a high risk of kidney failure, cardiovascular events, and all-cause mortality in Japanese patients with nondialysis-dependent CKD under nephrology care.
- 1 December 2021
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 16 (12) , 1797-1804
Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
Background and objective: Polypharmacy is common in patients with CKD and reportedly associated with adverse outcomes. However, its effect on kidney outcomes among patients with CKD has not been adequately elucidated. Hence, this investigation was aimed at exploring the association between polypharmacy and kidney failure requiring KRT. Design, setting, participants, and measurements: We retrospectively examined 1117 participants (median age, 66 years; 56% male; median eGFR, 48 ml/min per 1.73 m2) enrolled in the Fukushima CKD Cohort Study to investigate the association between the number of prescribed medications and adverse outcomes such as kidney failure, all-cause mortality, and cardiovascular events in Japanese patients with nondialysis-dependent CKD. Polypharmacy and hyperpolypharmacy were defined as the regular use of 5–9 and ≥10 medications per day, respectively. Results: The median number of medications was eight; the prevalence of polypharmacy and hyperpolypharmacy was each 38%. During the observation period (median, 4.8 years), 120 developed kidney failure, 153 developed cardiovascular events, and 109 died. Compared with the use of fewer than five medications, adjusted hazard ratios (95% confidence intervals) associated with polypharmacy and hyperpolypharmacy were 2.28 (1.00 to 5.21) and 2.83 (1.21 to 6.66) for kidney failure, 1.60 (0.85 to 3.04) and 3.02 (1.59 to 5.74) for cardiovascular events, and 1.25 (0.62 to 2.53) and 2.80 (1.41 to 5.54) for all-cause mortality. Conclusions: The use of a high number of medications was associated with a high risk of kidney failure, cardiovascular events, and all-cause mortality in Japanese patients with nondialysis-dependent CKD under nephrology care.